Physician profile
Matthew Eisenstein
NPI 1578114377
$1,632.67
in general payments reported to CMS, 2019-2025
15 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $577 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.52 | 2024-2025 | |
| Incyte Corporation | $227.44 | 2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $220.85 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $163.58 | 2025 | Adbry |
| Pfizer INC. | $120.10 | 2024 | |
| Sun Pharmaceutical Industries INC. | $118.86 | 2024-2025 | |
| Dermavant Sciences, INC. | $98.02 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $86.43 | 2024 | Dupixent |
| Mayne Pharma Commercial LLC | $70.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $57.91 | 2025 | |
| Botanix Sb INC | $40.55 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.47 | 2025 | Cabtreo, Jublia, Siliq |
| Janssen Biotech, INC. | $26.52 | 2024 | Tremfya |
| Genzyme Corporation | $24.25 | 2024 | |
| Organon LLC | $19.96 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eisenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.